Статья
Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020
Russian Society of Cardiology (RSC)With the participation: Association of Cardiovascular Surgeons of Russia, Russian Respiratory Society, Federation of Anesthesiologists and Resuscitators, Association of Rheumatologists of Russia, National Congress of Radiation Diagnosticians.
1. Howick JH. The Philosophy of Evidence-based Medicine. Wiley. p. 15. ISBN: 978-1-4443- 4266-6.
2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) “Об основах охраны здоровья граждан в Российской Федерации”.
3. Эпидемиологический словарь, 4-е издание. Под редакцией Джона М. Ласта для Международной эпидемиологической ассоциации. Москва, 2009, с. 316.
4. Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005.
5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) “Об обращении лекарственных средств”.
6. Galiè N, Humbert M, Vachiery JL, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.
7. Малая медицинская энциклопедия. М.: Медицинская энциклопедия. 1991-96 гг. http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.
8. Андреева НАУЧНЫЙ СОТРУДНИК, Реброва О.Ю., Зорин Н.А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.
9. Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:37-45. doi:10.1016/j.ijcard.2018.08.082.
10. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1):1801889. doi:10.1183/13993003.01889-2018.
11. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913. doi:10.1183/13993003.01913-2018.
12. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009 Oct;34(4):888- 94. doi:10.1183/09031936.00145608.
13. Callan P, Clark AL. Right heart catheterisation: indications and interpretation. Heart. 2016 Jan;102(2):147-57. doi:10.1136/heartjnl-2015-307786.
14. Hemnes AR, Zhao M, West J, et al. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2016 Aug 15;194(4):464-75. doi:10.1164/rccm.201508-1678OC.
15. Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019 Jan 24;53(1):1801916. doi:10.1183/13993003.01916-2018.
16. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006 Sep 26;114(13):1417-31. doi:10.1161/CIRCULATIONAHA.104.503540.
17. Hoeper MM, Ghofrani HA, Grünig E, et al. Pulmonary Hypertension. Dtsch Arztebl Int. 2017 Feb 3;114(5):73-84. doi:10.3238/arztebl.2017.0073.
18. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30. doi:10.1164/rccm.200510-1668OC.
19. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13;122(2):164-72. doi:10.1161/CIRCULATIONAHA.109.898122.
20. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив. 2019;91(1):10-31.
21. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216-23. doi:10.7326/0003-4819-107-2-216.
22. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 Jul 13;122(2):156-63. doi:10.1161/CIRCULATIONAHA.109.911818.
23. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb;137(2):376-87. doi:10.1378/chest.09-1140.
24. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013 Sep 30;168(2):871-80. doi:10.1016/j.ijcard.2012.10.026.
25. Ling Y, Johnson MK, Kiely DG et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6. doi:10.1164/rccm.201203-0383OC.
26. Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:53-62. doi:10.1016/j.ijcard.2018.08.080.
27. Mehra P, Mehta V, Sukhija R, et al. Pulmonary hypertension in left heart disease. Arch Med Sci. 2019 Jan;15(1):262-273. doi:10.5114/aoms.2017.68938.
28. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24;53(1):1801914. doi:10.1183/13993003.01914-2018.
29. Raghu G, Nathan SD, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J. 2015 Nov;46(5):1370-7. doi:10.1183/13993003.01537-2014.
30. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005 May;25(5): 783-8. doi:10.1183/09031936.05.00083404.
31. Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017 Mar 29;26(143):160112. doi:10.1183/16000617.0112-2016.
32. Pepke-Zaba J, Jansa P, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J. 2013 Apr;41(4):985-90. doi:10.1183/09031936.00201612.
33. Wilkens H, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:69-78. doi:10.1016/j.ijcard.2018.08.079.
34. Чазова И.Е., Мартынюк Т.В., Валиева З.С. и др. Оценка бремени хронической тромбоэмболической легочной гипертензии в Российской Федерации. Терапевтический архив. 2018;(9):101-9.
35. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1):1801887. doi:10.1183/13993003.01887-2018.
36. Chaudhary KR, Taha M, Cadete VJ, et al. Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse? Circ Res. 2017 Apr 14;120(8):1237-1239. doi:10.1161/CIRCRESAHA.116.310097.
37. Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 1;272S:4-10. doi:10.1016/j.ijcard.2018.09.070.
38. Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016 Mar 21;37(12):942-54. doi:10.1093/eurheartj/ehv512.
39. Авдеев С.Н. Легочная гипертензия при хронической обструктивной болезни легких. Системные гипертензии. 2004;1:5-11.
40. Klinger JR. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. Cardiol Clin. 2016 Aug;34(3):413-33. doi:10.1016/j.ccl.2016.04.003.
41. Awdish R, Cajigas H. Definition, epidemiology and registries of pulmonary hypertension. Heart Fail Rev. 2016 May;21(3):223-8. doi:10.1007/s10741-015-9510-y.
42. Чазова И.Е., Архипова О.А., Валиева З.С. и др. Легочная гипертензия в России: первые результаты национального регистра. Терапевтический архив. 2014;86(9):56-64.
43. Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801904. doi:10.1183/13993003.01904-2018.
44. Симакова М.А., Шлойдо Е.А., Зверев Д.А. и др. Рецидивирующее легочное кровотечение у беременной с идиопатической легочной артериальной гипертензией: клинический случай и обзор литературы. Пульмонология. 2014;(5):114-9.
45. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007 Aug 14;50(7):634-42. doi:10.1016/j.jacc.2007.04.056.
46. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;(9):4-23.
47. Keeling D, Mackie I, Moore GW, et al.; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Apr;157(1):47-58. doi:10.1111/j.1365-2141.2012.09037.x.
48. Basyal B, Jarrett H, Barnett CF. Pulmonary Hypertension in HIV. Can J Cardiol. 2019 Mar;35(3):288-298. doi:10.1016/j.cjca.2019.01.005.
49. Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J. 2011 May;37(5):1096-103. doi:10.1183/09031936.00089610.
50. Rich JD, Thenappan T, Freed B, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013 Aug 10;167(3):669-76. doi:10.1016/j.ijcard.2012.03.071.
51. Sun PY, Jiang X, Gomberg-Maitland M, et al. Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest. 2012 Feb;141(2):374-380. doi:10.1378/chest.10-3331.
52. Mercurio V, Peloquin G, Bourji KI, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018 AprJun;8(2):2045894018769874. doi:10.1177/2045894018769874.
53. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013 Sep 1;167(5):2300-5. doi:10.1016/j.ijcard.2012.06.024.
54. Milne EN. Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. Radiographics. 2012 Jul-Aug;32(4):1085-7. doi:10.1148/rg.324125021.
55. Trip P, Nossent EJ, de Man FS, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J. 2013 Dec;42(6):1575-85. doi:10.1183/09031936.00184412.
56. Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007 May;29(5):944-50. doi:10.1183/09031936.00134506.
57. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19;41(6):1028-35. doi:10.1016/s0735-1097(02)02964-9.
58. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi:10.1183/09031936.05.00035205.
59. Hadinnapola C, Bleda M, Haimel M, et al.; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation. 2017 Nov 21;136(21):2022- 2033. doi:10.1161/CIRCULATIONAHA.117.028351.
60. Jilwan FN, Escourrou P, Garcia G, et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013;143(1):47-55. doi:10.1378/chest.11-3124.
61. Rafanan AL, Golish JA, Dinner DS, et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest. 2001;120(3):894-9. doi:10.1378/chest.120.3.894.
62. Castro-Añón O, Golpe R, Pérez-de-Llano LA, et al. Haemodynamic effects of noninvasive ventilation in patients with obesity-hypoventilation syndrome. Respirology. 2012;17(8):1269-74. doi:10.1111/j.1440-1843.2012.02252.x.
63. Masa JF, Corral J, Caballero C, et al. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016;71(10):899-906. doi:10.1136/thoraxjnl-2016-208501.
64. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. doi:10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(4):412. Erratum in: Eur Heart J Cardiovasc Imaging. 2016;17(9):969.
65. Magnino C, Omedè P, Avenatti E, et al.; RIGHT1 Investigators. Inaccuracy of Right Atrial Pressure Estimates Through Inferior Vena Cava Indices. Am J Cardiol. 2017;120(9):1667-73. doi:10.1016/j.amjcard.2017.07.069.
66. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713; quiz 786-8. doi:10.1016/j.echo.2010.05.010.
67. Focardi M, Cameli M, Carbone SF, et al. Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2015;16(1):47-52. doi:10.1093/ehjci/jeu156.
68. Hellenkamp K, Unsöld B, Mushemi-Blake S, et al. Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension. J Am Soc Echocardiogr. 2018;31(1):89-98. doi:10.1016/j.echo.2017.09.009.
69. Kaemmerer H, Apitz C, Brockmeier K et al. Pulmonary hypertension in adults with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:79-88. doi:10.1016/j.ijcard.2018.08.078.
70. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e637-e697. doi:10.1161/CIR.0000000000000602. Erratum in: Circulation. 2019;139(14):e831-e832.
71. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. doi:10.1183/13993003.01915-2018.
72. Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-4. doi:10.2967/jnumed.106.039438.
73. Leblanc M, Leveillée F, Turcotte E. Prospective evaluation of the negative predictive value of V/Q SPECT using 99mTc-Technegas. Nucl Med Commun. 2007;28(8):667-72. doi:10.1097/MNM.0b013e32827a8e99.
74. Grüning T, Drake BE, Farrell SL, Nokes T. Three-year clinical experience with VQ SPECT for diagnosing pulmonary embolism: diagnostic performance. Clin Imaging. 2014;38(6):831-5. doi:10.1016/j.clinimag.2014.04.003.
75. Meng JJ, Zhang LJ, Wang Q, et al.. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(3):177-81. Chinese.
76. Lau EM, Bailey DL, Bailey EA, et al. Pulmonary hypertension leads to a loss of gravity dependent redistribution of regional lung perfusion: a SPECT/CT study. Heart. 2014;100(1):47-53. doi:10.1136/heartjnl-2013-304254.
77. Rajaram S, Swift AJ, Telfer A, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013;68(7):677-8. doi:10.1136/thoraxjnl2012-203020.
78. Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging. 2017;46(6):1693-7. doi:10.1002/jmri.25714.
79. Rajaram S, Swift AJ, Condliffe R, et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax. 2015;70(4):382-7. doi:10.1136/thoraxjnl-2014-206088.
80. Tan RT, Kuzo R, Goodman LR, et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest. 1998;113(5):1250-6. doi:10.1378/chest.113.5.1250.
81. Shen Y, Wan C, Tian P, et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine (Baltimore). 2014;93(27):e256. doi:10.1097/MD.0000000000000256.
82. Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004;183(1):65-70. doi:10.2214/ajr.183.1.1830065.
83. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2009;33(1):189-200. doi:10.1183/09031936.00090608.
84. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23(4):637-48. doi:10.1183/09031936.04.00079704.
85. Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol. 2009;71(1):49-54. doi:10.1016/j.ejrad.2008.03.016.
86. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. На пути оптимизации подходов к лечению хронической тромбоэмболической легочной гипертензии. Сonsilium Medicum. 2016;(5):53-8.
87. Марукян Н.В., Симакова М. А., Карпова Д.В. и др. Реперфузионный отек легкого как осложнение баллонной ангиопластики легочной артерии у пациентов с хронической тромбоэмболической легочной гипертензией Флебология. 2017;11(4):243-8.
88. Giordano J, Khung S, Duhamel A, et al. Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): Dual-energy CT experience in 31 patients. Eur Radiol. 2017;27(4):1631-9. doi:10.1007/s00330-016-4500-6.
89. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394-402. doi:10.1183/09031936.00012914.
90. Nawaz A, Litt HI, Stavropoulos SW, et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2008;19(11):1582-8. doi:10.1016/j.jvir.2008.07.011.
91. Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev. 2013;22(130):526-34. doi:10.1183/09059180.00006313.
92. Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson. 2012;14(1):40. doi:10.1186/1532-429X-14-40.
93. Swift AJ, Rajaram S, Hurdman J, et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imaging. 2013;6(10):1036-47. doi:10.1016/j.jcmg.2013.01.013.
94. Симакова М.А., Рыжков А.В., Казымлы А.В. и др. Перспективы использования показателей жесткости легочной артерии для оценки прогноза пациентов с легочной артериальной гипертензией. Терапевтический архив. 2018;90(1):86-92.
95. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250-7. doi:10.1093/eurheartj/ehl477.
96. Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging. 2014;7(1):107-14. doi:10.1161/CIRCIMAGING.113.000629. Erratum in: Circ Cardiovasc Imaging. 2017 Feb;10(2).
97. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511-9. doi:10.1016/j.jacc.2011.06.068.
98. Ley S, Kauczor HU, Heussel CP, et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2003;13(10):2365-71. doi:10.1007/s00330-003-1878-8.
99. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly. 2003;133(11-12):163-9.
100. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546-52. doi:10.1016/j.jacc.2006.07.061.
101. Kovacs G, Avian A, Pienn M, et al. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med. 2014;190(3):252-7. doi:10.1164/rccm.201402-0269PP.
102. Lammi MR, Saketkoo LA, Gordon JK, Steen VD. Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. Pulm Circ. 2018;8(2):2045893218757404. doi:10.1177/2045893218757404.
103. Frost AE, Farber HW, Barst RJ, et al. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013;143(1):185-95. doi:10.1378/chest.11-1387.
104. Abraham WT, Adamson PB, Bourge RC, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66. doi:10.1016/S0140-6736(11)60101-3. Erratum in: Lancet. 2012;379(9814):412.
105. Prasad A, Hastings JL, Shibata S, et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010;3(5):617-26. doi:10.1161/CIRCHEARTFAILURE.109.867044.
106. Fujimoto N, Borlaug BA, Lewis GD, et al. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127(1):55-62. doi:10.1161/CIRCULATIONAHA.112.111302.
107. Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J. 2013;42(4):1083-91. doi:10.1183/09031936.00091212.
108. Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail. 2014;7(1):116-22. doi:10.1161/CIRCHEARTFAILURE.113.000468.
109. Vachiéry JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. doi:10.1183/13993003.01897-2018.
110. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588-95. doi:10.1161/CIRCHEARTFAILURE.109.930701.
111. Hager WD, Collins I, Tate JP, et al. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients. Clin Respir J. 2013;7(3):227-36. doi:10.1111/j.1752-699X.2012.00310.x.
112. Maor E, Grossman Y, Balmor RG, et al. Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail. 2015;17(2):151-8. doi:10.1002/ejhf.198.
113. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):535-41. doi:10.1164/ajrccm.160.2.9811062.
114. Opitz CF, Blindt R, Blumberg F, et al. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011;154 Suppl 1:S13-9. doi:10.1016/S0167-5273(11)70489-2.
115. Grünig E, Benjamin N, Krüger U, et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:30-6. doi:10.1016/j.ijcard.2018.08.085.
116. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000;35(1):176-82. doi:10.1016/s0735-1097(99)00494-5.
117. Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):65-9. doi:10.1038/ng.2844.
118. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354-62. doi:10.1378/chest.11-0676.
119. Escribano-Subias P, Blanco I, López-Meseguer M, et al.; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596-603. doi:10.1183/09031936.00101211.
120. Lee WT, Ling Y, Sheares KK, et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J. 2012;40(3):604-11. doi:10.1183/09031936.00196611.
121. Medrek SK, Sahay S. Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. Chest. 2018;153(2):310-20. doi:10.1016/j.chest.2017.08.1159.
122. Talwar A, Sahni S, Talwar A, et al. Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation. Pulm Circ. 2016;6(2):191-5. doi:10.1086/686489.
123. Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187(3):303-10. doi:10.1164/rccm.201207-1290OC.
124. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940-6. doi:10.1136/annrheumdis-2012-202489.
125. Poms AD, Turner M, Farber HW, et al. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(1):169-76. doi:10.1378/chest.11-3241.
126. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192-201. doi:10.1016/j.jacc.2012.01.083.
127. Казымлы А.В., Березина А.В., Рыжков А.В. и др. Кардиопульмональное тестирование как метод оценки степени тяжести пациентов с прекапиллярной легочной гипертензией. Кардиология. 2014;54(12):22-8.
128. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-81. doi:10.1093/eurheartj/ehx257.
129. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. doi:10.1183/13993003.00740-2017.
130. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017.
131. Hoeper MM, Pittrow D, Opitz C, et al. Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018;51(3):1702606. doi:10.1183/13993003.02606-2017.
132. Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66(6):831-6. doi:10.1097/01.psy.0000145593.37594.39.
133. Алехин А. Н., Андреева Е.В., Трифонова Е.А. и др. Социальная и психологическая адаптация пациентов с синдромом Эйзенменгера. Научные заметки института Лесгафта. 2012;91(9):14-22.
134. Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev. 2017;1(1):CD011285. doi:10.1002/14651858.CD011285.pub2.
135. Chia KS, Wong PK, Faux SG, et al. The benefit of exercise training in pulmonary hypertension: a clinical review. Intern Med J. 2017;47(4):361-9. doi:10.1111/imj.13159.
136. Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J. 2016;37(1):35-44. doi:10.1093/eurheartj/ehv337.
137. Yuan P, Yuan XT, Sun XY, et al. Exercise training for pulmonary hypertension: a systematic review and meta-analysis. Int J Cardiol. 2015;178:142-6. doi:10.1016/j.ijcard.2014.10.161.
138. Pandey A, Garg S, Khunger M, et al. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail. 2015;8(6):1032-43. doi:10.1161/CIRCHEARTFAILURE.115.002130. Erratum in: Circ Heart Fail. 2015;8(6):1143.
139. Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40. doi:10.1186/s12890-015-0031-1.
140. Steppan J, Diaz-Rodriguez N, Barodka VM, et al. Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. Cureus. 2018;10(1):e2072. doi:10.7759/cureus.2072.
141. Thangamathesvaran L, Armenia SJ, Merchant AM. The effect of pulmonary hypertension on inpatient outcomes of laparoscopic procedures. Updates Surg. 2018;70(4):521-8. doi:10.1007/s13304-018-0556-y.
142. Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015;70(1):56-70. doi:10.1111/anae.12831.
143. Sarkar MS, Desai PM. Pulmonary hypertension and cardiac anesthesia: Anesthesiologist’s perspective. Ann Card Anaesth. 2018;21(2):116-22. doi:10.4103/aca.ACA_123_17.
144. Díaz-Gómez JL, Ripoll JG, Mira-Avendano I, et al. Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. South Med J. 2018;111(1):64-73. doi:10.14423/SMJ.0000000000000755.
145. Легочная гипертензия. Под редакцией С.Н. Авдеева. Москва. ГЭОТАРМедиа. 2019. 608 с.
146. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. doi:10.1016/j.chest.2018.11.030.
147. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580-7. doi:10.1161/01.cir.70.4.580.
148. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 1985;60(1):16-25. doi:10.1016/s0025-6196(12)65277-x.
149. Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;132(25):2403-11. doi:10.1161/CIRCULATIONAHA.115.018435.
150. Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2012;14(5):R213. doi:10.1186/ar4051.
151. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57- 65. doi:10.1161/CIRCULATIONAHA.113.004526.
152. Said K. Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry. Glob Cardiol Sci Pract. 2014;2014(2):48-52. doi:10.5339/gcsp.2014.25.
153. Roldan T, Rios JJ, Villamañan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ. 2017;7(3):692-701. doi:10.1177/2045893217721903.
154. Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis. 2012;7(3):268-76. doi:10.1111/j.1747-0803.2012.00633.x.
155. Гончарова Н. С., Симакова М.А., Моисеева О. М. Антитромботическая терапия у пациентов с легочной артериальной гипертензией. Артериальная гипертензия. 2019;25(1):25-33.
156. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28(3):768-72. doi:10.1016/0735-1097(96)00196-9.
157. Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/eurheartj/ehw210.
158. Jentzer JC, Mathier MA. Pulmonary Hypertension in the Intensive Care Unit. J Intensive Care Med. 2016;31(6):369-85. doi:10.1177/0885066615583652.
159. Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA Education. 2017;17(7):228-34.
160. Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38(6):1453-60. doi:10.1183/09031936.00037711.
161. Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55(2):180-6. doi:10.1016/j.pcad.2012.06.002.
162. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. doi:10.1056/NEJM199207093270203.
163. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009;18(111):29-34. doi:10.1183/09059180.00011111.
164. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26(18):1895-902. doi:10.1093/eurheartj/ehi283.
165. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-4. doi:10.1183/09031936.06.00057906.
166. McLaughlin VV, Oudiz RJ, Frost A, T et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-63. doi:10.1164/rccm.200603-358OC.
167. Frost AE, the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2007;175: Suppl., A1001.
168. Zheng Y, Yang T, Chen G, et al. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol. 2014;70(1):13-21. doi:10.1007/s00228-013-1583-8.
169. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68(2):357- 418. doi:10.1124/pr.115.011833.
170. Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis. 2014;8(5):202-16. doi:10.1177/1753944714541511.
171. Aversa M, Porter S, Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf. 2015;38(5):419-35. doi:10.1007/s40264-015-0275-y.
172. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529-35. doi:10.1016/j.jacc.2005.04.050.
173. Galiè N, Olschewski H, Oudiz RJ, et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9. doi:10.1161/CIRCULATIONAHA.107.742510.
174. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122-9. doi:10.1378/chest.08-1028.
175. Rivera-Lebron BN, Risbano MG. Ambrisentan: a review of its use in pulmonary arterial hypertension. Ther Adv Respir Dis. 2017;11(6):233-44. doi:10.1177/1753465817696040.
176. Vachiéry JL, Hoeper MM, Peacock AJ, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart Lung Transplant. 2017;36(4):399-406. doi:10.1016/j.healun.2016.04.013.
177. Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373-7. doi:10.1016/j.amjcard.2012.06.040.
178. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet. 2001;358(9288):1119-23. doi:10.1016/S0140-6736(01)06250-X.
179. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9. doi:10.1183/09031936.04.00028404.
180. Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-100. doi:10.1016/S0140-6736(08)60919-8.
181. Galiè N, Beghetti M, Gatzoulis MA, et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54. doi:10.1161/CIRCULATIONAHA.106.630715.
182. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-95. doi:10.1093/eurheartj/ehi728.
183. Fattinger K, Funk C, Pantze M, et al.The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69(4):223-31. doi:10.1067/mcp.2001.114667.
184. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13. doi:10.1183/13993003.02044-2014.
185. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-45. doi:10.1124/jpet.108.142976.
186. Pulido T, Adzerikho I, Channick RN, et al.; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809- 18. doi:10.1056/NEJMoa1213917.
187. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1-8. doi:10.1016/j.jchf.2014.07.013.
188. Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7(7):594-604. doi:10.1016/S2213-2600(19)30091-8.
189. Grünig E, Ohnesorge J, Benjamin N, et al. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Respiration. 2017;94(1):26-37. doi:10.1159/000470916.
190. Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep. 2013;15(5):475-83. doi:10.1007/s11906-013-0377-9.
191. Galiè N, Ghofrani HA, Torbicki A, et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. doi:10.1056/NEJMoa050010. Erratum in: N Engl J Med. 2006;354(22):2400-1.
192. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43(7):1149-53. doi:10.1016/j.jacc.2003.10.056.
193. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124-31. doi:10.1093/eurheartj/ehq011.
194. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151(4):851.e1-5. doi:10.1016/j.ahj.2005.09.006.
195. Мартынюк Т.В., Чазова И.Е. Роль силденафила в лечении пациентов легочной артериальной гипертензией. Системные гипертензии. 2012;(2):23-9.
196. Ghofrani HA, Humbert M, Langleben D, et al. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest. 2017;151(2):468-80. doi:10.1016/j.chest.2016.05.024.
197. Ghofrani HA, Galiè N, Grimminger F, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. doi:10.1056/NEJMoa1209655.
198. Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4(5):361-71. doi:10.1016/S2213-2600(16)30019-4.
199. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874-80. doi:10.1183/09031936.00137511.
200. Sitbon O, Channick R, Chin KM, et al.; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. doi:10.1056/NEJMoa1503184.
201. Lang I, Gaine S, Galie N, et al. Effect of selexipag on long term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study. Eur Heart J. 2015;36(suppl 1):381-2.
202. Fox BD, Shtraichman O, Langleben D, et al. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol. 2016;32(12):1520- 30. doi:10.1016/j.cjca.2016.03.004.
203. Lajoie AC, Lauzière G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291-305. doi:10.1016/S2213-2600(16)00027-8. Erratum in: Lancet Respir Med. 2016;4(6):e34.
204. Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Clin Exp Rheumatol. 2018;36(6):1095-102.
205. Vachiéry JL, Galiè N, Barberá JA, et al.; AMBITION Study Group. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38(2):194-202. doi:10.1016/j.healun.2018.11.006.
206. Coghlan JG, Channick R, Chin K, et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018;18(1):37-47. doi:10.1007/s40256-017-0262-z.
207. Sitbon O, Jaïs X, Savale L, Cottin V, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. doi:10.1183/09031936.00116313.
208. Burks M, Stickel S, Galiè N. Pulmonary Arterial Hypertension: Combination Therapy in Practice. Am J Cardiovasc Drugs. 2018;18(4):249-57. doi:10.1007/s40256-018-0272-5.
209. Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425. doi:10.1183/13993003.02425-2016.
210. Politi MT, Caruson NA, Lescano J, et al. Switch from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension: a real-world study J Heart Lung Transplant. 2017;36(4S):S166.
211. Blok IM, van Riel ACMJ, van Dijk APJ, et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol. 2017;227:51-52. doi:10.1016/j.ijcard.2016.11.211.
212. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131(4):977-83. doi:10.1378/chest.06-1227.
213. Горбачевский С.В., Пурсанов М.Г., Шмальц А.А. и др. Результаты атриосептостомии со стентированием у больных с идиопатической и схожими формами легочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019;(2):100-13.
214. Khan MS, Memon MM, Amin E, et al. Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Chest. 2019;156(1):53-63. doi:10.1016/j.chest.2019.03.003.
215. Bartolome SD, Torres F. Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016;21(3):347- 56. doi:10.1007/s10741-016-9562-7.
216. Sonnweber T, Pizzini A, Tancevski I, et al. Anaemia, iron homeostasis and pulmonary hypertension: a review. Intern Emerg Med. 2020;15(4):573-85. doi:10.1007/s11739-020-02288-1.
217. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019;53(1):1801906. doi:10.1183/13993003.01906-2018.
218. Gatzoulis MA, Beghetti M, Landzberg MJ, Galiè N. Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions. Int J Cardiol. 2014;177(2):340-7. doi:10.1016/j.ijcard.2014.09.024.
219. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039-50. doi:10.1161/CIRCULATIONAHA.105.592386.
220. Lopes AA, O’Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young. 2009;19(5):431-5. doi:10.1017/S1047951109990771.
221. Bruch L, Winkelmann A, Sonntag S, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol. 2008;21(1):44-9. doi:10.1111/j.1540-8183.2007.00324.x.
222. Kretschmar O, Sglimbea A, Corti R, Knirsch W. Shunt reduction with a fenestrated Amplatzer device. Catheter Cardiovasc Interv. 2010;76(4):564-71. doi:10.1002/ccd.22556.
223. Janjua AM, Saleem K, Khan I, et al. Double flap patch closure of VSD with elevated pulmonary vascular resistance: an experience at AFIC/NIHD. J Coll Physicians Surg Pak. 2011;21(4):197-201.
224. Talwar S, Keshri VK, Choudhary SK, et al. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac Cardiovasc Surg. 2014;148(6):2570-5. doi:10.1016/j.jtcvs.2013.10.052.
225. Gatzoulis MA, Beghetti M, Galiè N, et al.; BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27-32. doi:10.1016/j.ijcard.2007.04.078.
226. Gatzoulis MA, Landzberg M, Beghetti M, et al.; MAESTRO Study Investigators. Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation. 2019;139(1):51-63. doi:10.1161/CIRCULATIONAHA.118.033575.
227. Cavagna L, Codullo V, Ghio S, et al. Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients. Medicine (Baltimore). 2016;95(39):e4827. doi:10.1097/MD.0000000000004827.
228. Ahmed S, Palevsky HI. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am. 2014;40(1):103-24. doi:10.1016/j.rdc.2013.10.001.
229. Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181(12):1285-93. doi:10.1164/rccm.200909-1331PP.
230. Cottin V. Hypertension artérielle pulmonaire associée aux connectivites. Rev Mal Respir. 2006;23(4 Suppl): 13S61-72. French.
231. Hachulla E, Carpentier P, Gressin V, et al.; ItinérAIR-Sclérodermie Study Investigators. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford). 2009;48(3):304-8. doi:10.1093/rheumatology/ken488.
232. Hinchcliff M, Fischer A, Schiopu E, Steen VD; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011; 38(10):2172-9. doi:10.3899/jrheum.101243.
233. Young A, Vummidi D, Visovatti S, et al. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis Rheumatol. 2019;71(8):1339-49. doi:10.1002/art.40862.
234. Hsu VM, Chung L, Hummers LK, et al. Development of pulmonary hypertension in a highrisk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014;44(1):55-62. doi:10.1016/j.semarthrit.2014.03.002.
235. Gupta S, Gupta A, Rehman S, et al. Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. ERJ Open Res. 2019;5(1):00168-2018. doi:10.1183/23120541.00168-2018.
236. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383-94. doi:10.1378/chest.10-0260.
237. Coghlan JG, Denton CP, Grünig E, et al.; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-9. doi:10.1136/annrheumdis-2013-203301.
238. Волков А. В., Мартынюк Т. В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани: современное состояние проблемы. Научно-практическая ревматология. 2018;56(4):474-85.
239. Coghlan, J., Denton, C.P. Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension. Journal of Scleroderma and Related Disorders, 2018;3(1):30-8.
240. Günther S, Jaïs X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum. 2012;64(9):2995-3005. doi:10.1002/art.34501.
241. Lammi MR, Mathai SC, Saketkoo LA, et al.; Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2016;68(3):740-8. doi:10.1002/art.39478.
242. Coghlan JG, Galiè N, Barberà JA, et al.; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219-27. doi:10.1136/annrheumdis-2016-210236.
243. Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76(2):422-6. doi:10.1136/annrheumdis-2015-209087.
244. Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100(7):1440-52. doi:10.1097/TP.0000000000001229.
245. Sithamparanathan S, Nair A, Thirugnanasothy L, et al.; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017;36(7):770-9. doi:10.1016/j.healun.2016.12.014.
246. Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl. 2009;15(1):30-6. doi:10.1002/lt.21533.
247. Correale M, Palmiotti GA, Lo Storto MM, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45(5):515-28. doi:10.1111/eci.12427
248. Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res. 2011;12(1):103. doi:10.1186/1465-9921-12-103.
249. Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012;185(11):1235-43. doi:10.1164/rccm.201110-1909OC.
250. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24(1):67-75. doi:10.1097/QAD.0b013e328331c65e.
251. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-456. doi:10.1378/chest.11-1460.
252. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167(10):1433-9. doi:10.1164/rccm.200204-330OC.
253. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191-210. doi:10.1001/jama.2016.8900.
254. Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res. 2009;7(6):589-96. doi:10.2174/157016209789973583.
255. Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50(2):99-107. doi:10.1046/j.1365-2125.2000.00245.x.
256. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411-22. doi:10.2147/vhrm.2006.2.4.411.
257. Chinello P, Petrosillo N. Pharmacological treatment of HIV-associated pulmonary hypertension. Expert Rev Clin Pharmacol. 2016;9(5):715-25. doi:10.1586/17512433.2016.1151785.
258. Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J. 2004;23(2):321-6. doi:10.1183/09031936.03.00057703.
259. Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80(4):670-7. doi:10.1111/bcp.12650.
260. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-7. doi:10.1164/rccm.200404-445OC.
261. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009;33(1):92-8. doi:10.1183/09031936.00094808.
262. Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34. doi:10.1183/13993003.00026-2016.
263. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976-97. doi:10.1016/j.jacc.2015.03.540.
264. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164-74. doi:10.1161/CIRCULATIONAHA.110.983866.
265. Bonderman D, Ghio S, Felix SB, et al.; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502-11. doi:10.1161/CIRCULATIONAHA.113.001458.
266. Vachiéry JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51(2):1701886. doi:10.1183/13993003.01886-2017.
267. Bermejo J, Yotti R, García-Orta R, et al.; Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39(15):1255-64. doi:10.1093/eurheartj/ehx700.
268. Skoro-Sajer N, Marta G, Gerges C, et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax. 2014;69(2):116-22. doi:10.1136/thoraxjnl-2013-203746.
269. Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160111. doi:10.1183/16000617.0111-2016.
270. Jenkins DP, Biederman A, D’Armini AM, et al. Operability assessment in CTEPH: Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016;152(3):669-74.e3. doi:10.1016/j.jtcvs.2016.02.062.
271. Madani M, Ogo T, Simonneau G. The changing landscape of chronic thromboembolic pulmonary hypertension management. Eur Respir Rev. 2017;26(146):170105. doi:10.1183/16000617.0105-2017.
272. Kataoka M, Inami T, Kawakami T et al. Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension: A Japanese Perspective. JACC Cardiovasc Interv. 2019;12(14):1382-8. doi:10.1016/j.jcin.2019.01.237.
273. Ghofrani HA, D’Armini AM, Grimminger F, et al.; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. doi:10.1056/NEJMoa1209657.
274. Sugimura K, Fukumoto Y, Satoh K, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76(2):485-8. doi:10.1253/circj.cj-11-1217.
275. Sliwa K, van Hagen IM, Budts W, et al.; ROPAC investigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016;18(9):1119-28. doi:10.1002/ejhf.594. Epub 2016 Jul 7. Erratum in: Eur J Heart Fail. 2017;19(3):439.
276. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340.
277. Makino Y, Matsuda Y, Mitani M, et al. Risk factors associated with preterm delivery in women with cardiac disease. J Cardiol. 2012;59(3):291-8. doi:10.1016/j.jjcc.2011.11.006
278. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.
279. Pijuan-Domènech A, Galian L, Goya M, et al. Cardiac complications during pregnancy are better predicted with the modified WHO risk score. Int J Cardiol. 2015;195:149-54. doi:10.1016/j.ijcard.2015.05.076.
280. Vigl M, Kaemmerer M, Niggemeyer E, et al. Sexuality and reproductive health in women with congenital heart disease. Am J Cardiol. 2010;105(4):538-41. doi:10.1016/j.amjcard.2009.10.025.
281. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009;30(3):256-65. doi:10.1093/eurheartj/ehn597.
282. Roos-Hesselink JW, Budts W, Walker F, et al. Organisation of care for pregnancy in patients with congenital heart disease. Heart. 2017;103(23):1854-9. doi:10.1136/heartjnl-2017-311758.
283. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):431-7. doi:10.1183/16000617.0079-2016.
284. Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin Respir Crit Care Med. 2013;34(5):681-8. doi:10.1055/s-0033-1355438.
285. Hsu CH, Gomberg-Maitland M, Glassner C, Chen JH. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl. 2011;(172):6-14. doi:10.1111/j.1742-1241.2011.02711.x.
286. Chandrasekhar S, Cook CR, Collard CD. Cardiac surgery in the parturient. Anesth Analg. 2009;108(3):777-85. doi:10.1213/ane.0b013e31819367aa.
287. Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. Obstet Gynecol. 2015;126(1):22-8. doi:10.1097/AOG.0000000000000910.
288. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015;5(3):435- 65. doi:10.1086/682230.
289. Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016;316(9):952-61. doi:10.1001/jama.2016.12126.
290. Kelaranta A, Kaasalainen T, Seuri R, et al. Fetal radiation dose in computed tomography. Radiat Prot Dosimetry. 2015;165(1-4):226-30. doi:10.1093/rpd/ncv097. Erratum in: Radiat Prot Dosimetry. 2017;177(3):359-360.
291. Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012;40(4):881-5. doi:10.1183/09031936.00141211.
292. Treinen KA, Louden C, Dennis MJ, Wier PJ. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology. 1999;59(1):51-9. doi:10.1002/(SICI)1096-9926(199901)59:13.0.CO;2-I.
293. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. 2015 RCOG Green-top Guideline No. 37a. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
294. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-7. doi:10.1182/blood-2005-02-0626.
295. Terek D, Kayikcioglu M, Kultursay H, et al. Pulmonary arterial hypertension and pregnancy. J Res Med Sci. 2013;18:73-6.
296. Martin SR, Edwards A. Pulmonary Hypertension and Pregnancy. Obstet Gynecol. 2019;134(5):974-987. doi:10.1097/AOG.0000000000003549. Erratum in: Obstet Gynecol. 2020;135(4):978.
297. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-50. doi:10.1016/j.jacc.2013.10.032.
298. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. 2013;143(5):1330-6. doi:10.1378/chest.12-0528.
299. Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102(6):1133-7; discussion 5A-6A. doi:10.1097/00000542-200506000-00012.
300. Баутин А.Е., Якубов А.В., Коконина Ю.А. и др. Анестезиологическое обеспечение и интенсивная терапия в периоперационном периоде абдоминального родоразрешения у беременных с легочной артериальной гипертензией. Анестезиология и реаниматология. 2016;(6):455-61.
301. Hill W, Holy R, Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? Pulm Circ. 2018;10(4):2045894018785259. doi:10.1177/2045894018785259. Epub ahead of print.
302. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32(2):75-81. doi:10.1783/147118906776276486.
303. Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257-66. doi:10.1056/NEJMoa1111840.
304. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890. doi:10.1136/bmj.b2890.
305. Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. doi:10.1136/bmj.e4944.
306. Vieira CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod. 2007;22(8):2196-201. doi:10.1093/humrep/dem153.
307. Roos-Hesselink JW, Cornette J, Sliwa K, et al. Contraception and cardiovascular disease. Eur Heart J. 2015;36(27):1728-34, 1734a-1734b. doi:10.1093/eurheartj/ehv141.
308. Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev. 2017;8(8):CD001324. doi:10.1002/14651858.CD001324.pub5. Update in: Cochrane Database Syst Rev. 2019;1:CD001324.
309. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 1999;59(2):79-83. doi:10.1016/s0010-7824(99)00011-6.
310. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol. 2013;29 Suppl 1:1-14. doi:10.3109/09513590.2013.774591.
311. Jesam C, Cochon L, Salvatierra AM, et al. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception. 2016;93(4):310-6. doi:10.1016/j.contraception.2015.12.015.
312. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589- 96. doi:10.1183/09031936.00092311.
313. Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest. 2013;144(1):160-8. doi:10.1378/chest.12-2417.
314. Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1160-4. doi:10.1067/mje.2002.123962.
315. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. doi:10.1164/rccm.200604-547OC.
316. Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr. 2010;23(9):943-53. doi:10.1016/j.echo.2010.06.029.
317. Smith BC, Dobson G, Dawson D, et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 2014;64(1):41-51. doi:10.1016/j.jacc.2014.01.084.
318. Grünig E, Peacock AJ. Imaging the heart in pulmonary hypertension: an update. Eur Respir Rev. 2015;24(138):653-64. doi:10.1183/16000617.0058-2015.
319. Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension With Echocardiography. JACC Cardiovasc Imaging. 2016;9(6):733-46. doi:10.1016/j.jcmg.2016.02.022.
320. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-9. doi:10.1016/s0735-1097(02)01744-8.
321. Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011;139(6):1299-309. doi:10.1378/chest.10-2015.
322. Baggen VJ, Leiner T, Post MC, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and metaanalysis. Eur Radiol. 2016;26(11):3771-80. doi:10.1007/s00330-016-4217-6.
323. Kang KW, Chang HJ, Kim YJ, et al. Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension. Circ J. 2011;75(9):2244-51. doi:10.1253/circj.cj-10-1310.
324. Swift AJ, Rajaram S, Campbell MJ, et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014;7(1):100-6. doi:10.1161/CIRCIMAGING.113.000338.
325. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015;34(3):362-8. doi:10.1016/j.healun.2014.08.020.
326. Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17(4):647- 52. doi:10.1183/09031936.01.17406470.
327. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. doi:10.1161/01.cir.0000022687.18568.2a.
328. Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol. 2013;167(4):1193-8. doi:10.1016/j.ijcard.2012.03.135.
329. Blumberg FC, Arzt M, Lange T, et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail. 2013; 15(7):771-5. doi:10.1093/eurjhf/hft044.
330. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112(6):828-35. doi:10.1161/CIRCULATIONAHA.104.529800.
331. Arena R, Lavie CJ, Milani RV, et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. J Heart Lung Transplant. 2010;29(2):159-73. doi:10.1016/j.healun.2009.09.003.
332. Kovacs G, Herve P, Barbera JA, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50(5):1700578. doi:10.1183/13993003.00578-2017. Erratum in: Eur Respir J. 2018;51(1).
333. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013;8(9):e72013. doi:10.1371/journal.pone.0072013.
334. Anwar A, Ruffenach G, Mahajan A, et al. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016;17(1):88. doi:10.1186/s12931-016-0396-6.
335. Rosenthal JL, Jacob MS. Biomarkers in pulmonary arterial hypertension. Curr Heart Fail Rep. 2014;11(4):477-84. doi:10.1007/s11897-014-0225-5.
336. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007;131(2):402-9. doi:10.1378/chest.06-1758.
337. Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.
338. Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumoniaassociated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7(9):780-90. doi:10.1016/S2213-2600(19)30250-4.
339. Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В., Волков А.В. Клинический субтип системной склеродермии, ассоциированный с легочной артериальной гипертензией. Кардиологический вестник. 2017;XII(4):66-75.
340. Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020;41(44):4242.
341. Казымлы А.В., Рыжков А.В., Симакова М.А. и др. Значение двухмерной эхокардиографии в оценке степени тяжести пациентов с легочной гипертензией Кардиология. 2016;56(1):25-30.
342. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19(12):1845-55. doi:10.1053/euhj.1998.
343. Provencher S, Chemla D, Hervé P, et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2006;27(1):114-20. doi:10.1183/09031936.06.00042705.